Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114128 | 0.82 | PRKDC (0.34) | PRKDCKCNH2SYKHCAR2SMN1; SMN2 | |
| SCHEMBL17865262 | 0.82 | KCNH2 (0.40) | PRKDCKCNH2SYKHCAR2SMN1; SMN2 | |
| SCHEMBL17861201 | 0.77 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNA | |
| SCHEMBL17865259 | 0.76 | CYP3A4 (0.42) | PRKDCKCNH2SMN1; SMN2LMNACYP11B2 | |
| SCHEMBL7589137 | 0.74 | KDM4E (0.50) | SMN1; SMN2LMNACYP19A1 | |
| SCHEMBL2788882 | 0.74 | KDM4E (0.50) | SMN1; SMN2LMNACYP19A1 | |
| SCHEMBL7590836 | 0.74 | KDM4E (0.50) | SMN1; SMN2LMNACYP19A1 | |
| SCHEMBL17865254 | 0.72 | APLNR (0.41) | PRKDCKCNH2SYK | |
| SCHEMBL17847834 | 0.71 | CYP17A1 (0.44) | PRKDCKCNH2SMN1; SMN2LMNACYP11B2 | |
| SCHEMBL4908140 | 0.71 | CYP3A4 (0.42) | PRKDCKCNH2SYKSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-01-29 | — | — | US | disclosed |
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-01-29 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| WO-2016096126-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRM1, SIGMAR1 | PRKDC 2415/4885KCNH2 633/4885SYK 1389/4885 |
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | PRKDC 2415/4885KCNH2 633/4885SYK 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.